Genmab — Juni 2019
-
Aktieekspert: Flere selskaber kan være ude efter Genmab
En britisk aktieekspert, som for nylig forudsagde et opkøbstilbud på Nets før alle andre, mener at vide, at flere store medicinalselskaber kan være interesserede i at opkøbe Genmab.
(medwatch.dk)
-
Det hælder jeg også mest til pt. bibob og tak for link SB. Her er et lidt ældre indslag fra Novod https://medwatch.dk/Medicinal___Biotek/article9225014.ece
-
Why is the Hexabody CD38 deal positive news for Genmab? Genmab has to pay the entire sum of Hexabody cd38's development until it proofs to be beneficial to patients. Ones that is proved, J&J can execise their right to commercialize it. I would say if Genmab has to go all the way alone until hexabody CD38 has proven to work, why not wait to make a deal til that point? Please illuminate me.
-
Bulder. Mit spørgsmål om Hexa bliver besvaret her. Sorry. https://m.firstwordpharma.com/johnson-johnson-genmab-look-develop-darzalex-follow
-
Vedr. hex-cd38 PoC: Når man tænker på at dara, pom, dex i RRMM blev godkendt af FDA pba Equulius, som var et fase 1B studie, så skulle det være muligt at tilrettelægge et enkelt klinisk studie således, at Janssen får set nok til at afgøre om de vil smide penge efter det.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind